

**International Nonproprietary Names (INN)
for biological and biotechnological substances**
(a review)



**World Health
Organization**

INN Working Document 05.179
Distr.: GENERAL
ENGLISH ONLY
2011

**International Nonproprietary Names (INN)
for biological and biotechnological substances**
(a review)



**World Health
Organization**

Programme on International Nonproprietary Names (INN)
Quality Assurance and Safety: Medicines
Essential Medicines and Pharmaceutical Policies (EMP)

**International Nonproprietary Names (INN)
for biological and biotechnological substances**

(a review)

© World Health Organization 2011

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed by the WHO Document Production Services, Geneva, Switzerland

CONTENTS

0. INTRODUCTION.....	iv
1. PHARMACOLOGICAL CLASSIFICATION OF BIOLOGICAL AND BIOTECHNOLOGICAL SUBSTANCES	1
2. CURRENT STATUS OF EXISTING STEMS OR SYSTEMS FOR BIOLOGICAL AND BIOTECHNOLOGICAL SUBSTANCES	4
2.1. Groups with respective stem	4
2.2. Groups with respective pre-stems	5
2.3. Groups with INN schemes	5
2.4. Groups without respective stems / pre-stems and without INN schemes	5
3. GENERAL POLICIES FOR BIOLOGICAL AND BIOTECHNOLOGICAL SUBSTANCES	6
3.1. General policies for blood products	6
3.2. General policies for fusion proteins	6
3.3. General policies for gene therapy products	6
3.4. General policies for glycosylated compounds	7
3.5. General policies for immunoglobulins fractionated from plasma	8
3.6. General policies for monoclonal antibodies	8
3.7. General policies for non-glycosylated compounds	11
3.8. General policies for skin substitutes	11
3.9. General policies for transgenic products	11

3.10.	General policies for vaccines	11
4.	SUMMARY OF INN ASSIGNED TO BIOLOGICAL AND BIOTECHNOLOGICAL SUBSTANCES	13
4.1.	Antimicrobial, bactericidal permeability increasing polypeptides	13
4.2.	Antisense oligonucleotides	13
4.3.	Antithrombins	13
4.4.	Blood coagulation cascade inhibitors	14
4.5.	Blood coagulation factors	14
4.6.	Colony stimulating factors	15
4.7.	Enzymes	16
4.8.	Erythropoietin type blood factors	19
4.9.	Gene therapy products	19
4.10.	Growth factors	19
4.11.	Growth hormone (GH) derivatives	21
4.12.	Growth hormone antagonists	21
4.13.	Heparin derivatives including low molecular mass heparins	21
4.14.	Hirudin derivatives	22
4.15.	Pituitary hormone-release inhibiting peptides	22
4.16.	Insulins	22
4.17.	Interferons	23
4.18.	Interleukin receptor antagonists	24
4.19.	Interleukin type substances	24
4.20.	Monoclonal antibodies	26
4.21.	Oxytocin derivatives	28

4.22.	Peptides and glycopeptides (for special groups of peptides see <i>-actide</i> , <i>-pressin</i> , <i>-relin</i> , <i>-tocin</i>).....	28
4.23.	Peptide vaccines / recombinant vaccines.....	30
4.24.	Pituitary / placental glycoprotein hormones	31
4.25.	Pituitary hormone-release stimulating peptides.....	32
4.26.	Receptor molecules, native or modified	32
4.27.	Synthetic polypeptides with a corticotropin-like action	33
4.28.	Thrombomodulins.....	34
4.29.	Toxins	34
4.30.	Vasoconstrictors, vasopressin derivatives	34
4.31.	Various.....	34
5.	CURRENT CHALLENGES	39
	REFERENCES	40
	ANNEX 1.....	42
	The list of INN for composite proteins published	42
	ANNEX 2.....	50
	Transliteration of Greek letters in English, French and Spanish	50
	ANNEX 3.....	51
	The previous naming scheme for monoclonal antibodies.....	51

0. INTRODUCTION

More than 50 years ago, WHO established the International Nonproprietary Name (INN) Expert Group / WHO Expert Committee on Specifications for Pharmaceutical Preparations, to assign nonproprietary names to medicinal substances, so that each substance would be recognized globally by a unique name. These INNs do not give proprietary rights, unlike a trade mark, and can be used freely as they are public property.

INNs have been assigned to biological products since the early days of the INN Programme. As well as many names for individual substances, animal insulin preparations were given an INN in Recommended list 3 in 1959. In the period up to 1980, names were assigned to antibiotics, synthetic peptides, hormones and other proteins. In names of compounds related by structure and / or function, specific letter groups, called stems, are included to aid recognition by health professionals. The *-actide* for synthetic polypeptides with a corticotrophin-like action is an example.

In 1982, the name *insulin human* was proposed for the recombinant protein identical to natural human insulin, and since then names have been assigned to a growing number of recombinant products. Within the INN Programme, names have not been assigned to natural human blood products or vaccines. For those groups of biological products, the WHO Expert Committee on Biological Standardization (ECBS) has been adopting the scientific names of the biological products within the definitions of respective requirements.

Since the time when *insulin human* became the first recommended INN (rINN) for a recombinant product, the range of biological / biotechnological products has increased in size and complexity. For example, new stems have been introduced for tissue plasminogen activators (*-plase*) among other groups. Analogues of recombinant glycosylated proteins produced in different cell systems have been classified using Greek letters as indicators in the sequence of product introduction: erythropoietin (*epoetin alfa*, *beta* and so on) and glycoprotein hormones (*folliotropin*) are examples. In the 1990s, a systematic scheme for naming monoclonal antibodies was implemented, based on the stem *-mah* which indicates the origin (mouse human etc) of the antibody and its

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28885

